894 results about "Intravenous therapy" patented technology

The invention provides an image-based PICC (Peripherally Inserted Central Catheter) intravenous therapy information monitoring system and method, relates to the field of intelligent image analysis, and is used for judging whether a puncture part of a patient has an infection sign or not by performing time sequence analysis on high-definition images of the puncture part of the patient at different time points in a target monitoring time period. Therefore, the accuracy and timeliness of infection monitoring can be improved, and infection signs can be found in an early stage, so that measures can be taken in time, and the incidence rate and severity of infection are reduced.

The present disclosure provides methods of treating opioid use disorder in a patient in need thereof by intravenously administering to the patient a therapeutically effective amount of ibogaine or pharmaceutically acceptable salt thereof.

Methods of administering sotalol hydrochloride in an amount effective for treating one or more cardiovascular disease or disorder in pediatric patients are described and include IV and / or oral doses based on age-specific creatinine clearance ranges.

The invention discloses a construction method and application of a gene modified mesenchymal stem cell. The construction method comprises the following steps: constructing a recombinant lentivirus carrying PD-L1 and ICAM1 genes; the recombinant lentivirus carrying the PD-L1 gene and the ICAM1 gene is transfected with mesenchymal stem cells, and the mesenchymal stem cells are screened by puromycin, so that an engineered mesenchymal stem cell strain modified by the PD-L1 gene and the ICAM1 gene is obtained; the mesenchymal stem cells provided by the invention are modified by engineering genes of PD-L1 and ICAM1, and are screened by puromycin to obtain a mesenchymal stem cell strain capable of stably and highly expressing the genes of PD-L1 and ICAM1; after the mesenchymal stem cells highly expressing the PD-L1 and ICAM1 genes are intravenously injected into an autoimmune hepatitis animal model, the autoimmune hepatitis symptom can be remarkably relieved, the liver injury degree can be reduced, the expression of inflammatory factors can be regulated, the inflammatory reaction can be inhibited, and the obvious curative effect can be achieved.

The invention discloses a bionic nano-composite, a preparation method thereof and application of the bionic nano-composite in preparation of a product for treating atherosclerosis, and belongs to the technical field of medicine preparation. The bionic nano compound is a metal nano enzyme Ir-TiO2 coated by an M2 macrophage cell membrane. According to the invention, the surfaces of Ir-TiO2 nanoparticles are coated with M2 macrophage membranes, so that the nanocomposite with a bionic structure is prepared. After intravenous injection, the formed bionic nanocomposite can actively target endothelial cells in atherosclerotic lesions, and release Ir-TiO2 antagonism to endothelial cells in plaques and cytoplasm of inflammatory macrophages. After the Ir-TiO2 reaches the diseased region, the Ir-TiO2 can play an enzyme role to achieve an anti-inflammatory effect, and can promote inflammatory cells such as macrophages and smooth muscle cells at the diseased region to discharge cholesterol, reduce lipid deposition in the cells, reduce the generation of foam cells and promote the growth of plaques. The nanotherapy can effectively prevent the progress of atherosclerosis lesion inflammation and relieve atherosclerosis.

The invention discloses a pharmaceutical composition for reversing pancreatic cancer gemcitabine drug resistance and application of the pharmaceutical composition, and belongs to the technical field of biological medicine. The composition comprises a generic FGFR inhibitor delatinib and gemcitabine, the concentration of the delatinib is 25 to 50 mg / kg, and the concentration of the gemcitabine is 20 to 30 mg / kg. By inhibiting an FGFR2 / FGFR3 signal channel and reducing the expression of FGFR protein in drug-resistant cells, the chemosensitivity of gemcitabine is synergistically enhanced, the apoptosis induction rate is increased by more than two times, and the synergic index (CI) is less than 1. In-vitro and nude mouse transplantation tumor experiments prove that the composition can significantly inhibit the proliferation of gemcitabine drug-resistant pancreatic cancer cells. The Gemcitabine drug-resistant pancreatic cancer drug can be used for preparing a drug for treating Gemcitabine drug-resistant pancreatic cancer with high FGFR3 expression, patients are screened through immunohistochemistry or gene sequencing, intravenous injection or oral administration is adopted, dosage forms comprise freeze-dried powder injection, capsules or tablets, and a new strategy is provided for pancreatic cancer drug-resistant treatment.

Systems and methods for organizing medical tubing and / or wiring are disclosed herein. According to some embodiments, the present technology includes an organizer including a tubular member configured to be removably coupled to an intravenous (IV) pole in a vertical orientation. The tubular member can include a longitudinal axis, a lumen extending along the longitudinal axis, and a longitudinal slit connected to the lumen. The tubular member can be configured to separate at the longitudinal slit to insert and remove the IV pole from the lumen. The organizer can further include a plurality of holders coupled to the tubular member. The plurality of holders can include a first end, a second end opposite the first end, and a curved receiving region between the first and second ends. The curved receiving region can be configured to support tubing or wiring of a medical device coupled to the IV pole.

The disclosure relates to methods, compositions, and combinations for detoxification in a patient comprising performing therapeutic plasma exchange (TPE) on the patient. The disclosure also relates to methods, compositions, and combinations for removing toxins in a patient as a result of chronic exposure to the toxins, comprising performing one or more TPE sessions on the patient and administering an oral composition to the patient. The methods, compositions, and combinations of the disclosure may also be used to replenish biomarkers indicative of a healthy state of the body in order to improve immune system function or patient longevity, and / or reduce oxidative stress or inflammation. The methods, compositions, and combinations of the disclosure may also be used to reduce the level of atherosclerosis, improve cognitive function, prevent early cancer development, promote immune health, and / or treat health conditions or diseases such as autoimmune diseases, cancers, Alzheimer's disease, Parkinson's disease, chronic fatigue syndromes, or fibromyalgia. Additionally, the methods, compositions, and combinations of the disclosure may comprise an intravenous supplementation, wherein each TPE session is followed by administration to the patient of an IV composition. The disclosure further relates to oral compositions and IV compositions for use in the methods, compositions, and combinations of the disclosure.

The invention discloses an intravenous therapy information management system, method and device, and relates to the technical field of medical information management. The vein treatment information management system comprises an initial imaging definition analysis prompt module, a vein imaging definition operation optimization prompt module and a vein difference optimization prompt module. According to the method, the first definition judgment result is obtained by performing the first definition judgment on the vein depth blood vessel image, whether to perform probe intelligent assistance and information recording is judged according to the first definition judgment result, and then whether to perform vein difference analysis is judged according to the second definition judgment result obtained according to the obtained second vein depth blood vessel image; if vein difference analysis is carried out, a third definition judgment result is obtained according to the optimized vein image to judge whether vein difference optimization control is carried out or not, and the effect of improving the acquisition management accuracy of the vein depth blood vessel image is achieved; the problem that in the prior art, vein depth blood vessel images recorded by vein channel information management are inaccurate is solved.

The invention provides a fusion platform intelligent teaching method and system based on virtual simulation, and the method comprises the steps: obtaining an operation behavior of a student at each interaction point in a virtual simulation scene, and forming an IFM data set; constructing an evaluation function, and comparing the actual performance data with the ideal performance value; forming a key evidence source data set based on actual performance data in the IFM data set; and constructing an optimization model containing data conflict items and consistency items of each key evidence source, generating teaching guidance data, and quantitatively evaluating the learning effect of students. According to the invention, students can perform operation exercises in a simulated real clinical scene, such as key nursing skills of intravenous injection, external chest compression and the like, and through multi-dimensional data collection including operation accuracy, answer conditions, interactive records and the like, more comprehensive learning evaluation is provided, so that scoring deviation caused by single data is avoided, and the learning efficiency is improved. And a rich information basis is provided for ability evaluation of students.

The invention discloses an RGD-click chemical crosslinking siRNA nano-carrier, a preparation method thereof and application of the nano-carrier in preparation of a medicine for treating secondary thyroidism, and belongs to the technical field of medicines.The nano-carrier is RGD-PEG-PLys (N), and the preparation method of the nano-carrier comprises the steps of synthesis of PLys (ss-DBCO), synthesis of RGD-PEG-PLys (N) and the like. According to the application, the nano-carrier is used for preparing siRNA composite nanoparticles; vascular endothelial targeting (RGD), dynamic stability (click crosslinking) and microenvironment responsiveness (disulfide bond) are organically combined for the first time to achieve mutual synergistic interaction, and the effect ceiling of an existing material is broken through; according to the siRNA composite nanoparticle, the silence effect of the PTH gene as long as 70 days can be achieved through single intravenous injection, the PTH inhibition rate is larger than 85%, the siRNA accumulation amount in parathyroid gland tissue is remarkably increased through RGD targeting (8.6 times that of a non-targeting group), the liver and kidney distribution amount is reduced by 60%, and the system toxicity is controllable.

Some embodiments disclosed herein relate to a device for transferring precise amounts of fluid from at least one source container to at least one target container. In some embodiments, the fluid is first transferred from the source container (e.g., a vial) through a connector to an intermediate measuring container (e.g., a syringe). In some embodiments air can pass through an air inlet and enter the vial to compensate for the volume of fluid withdrawn from the vial. An air check valve or a bag or a filter can prevent the fluid from escaping through the air inlet. The precisely measured amount of fluid can then be transferred from the intermediate measuring container to the target container (e.g., an IV bag). In some embodiments the connector can include a source check valve and a target check valve to direct fluid first from the source container to the intermediate measuring container and then from the intermediate measuring container to the target container. Some embodiments of the device can include a motor and a controller for automatically actuating a plunger of the syringe to transfer the desired amount of fluid.

An anesthetic equipment storage and waste air management module configured to housing electronic and electromechanical surgical equipment including a system to measure and record administration of one or more IV medications or fluids for IV administration. The module can include a housing having a lower section and a tower-like upper section, wherein the lower section is configured to house unrelated waste heat-producing electronic and electromechanical surgical equipment. The module can also include a cowling that substantially confines waste heat generated by the unrelated waste heat-producing electronic and electromechanical surgical equipment, and can include a system for measuring and recording the administration of the one or more IV medications and fluids.

The invention discloses a robot assisted diagnosis and treatment system for a nuclear medicine ward and an application method. The robot assisted diagnosis and treatment system comprises an AI robot for non-contact assisted diagnosis and treatment; the robot library is arranged on the same layer of the nuclear medicine ward; the remote interaction platform is used for issuing related instructions and man-machine interaction to the AI robot; a radiation protection and monitoring module, an identity recognition module, a health propaganda and education module, a ferry module, a visual doctor-patient communication module, a communication module, an RFID access control module and an environment disinfection module are integrated on the AI robot; the AI robot is connected with an external subcutaneous injection module, an external intravenous injection module, an external medicine distribution module and an external living goods conveying module through corresponding switching assemblies. According to the robot-assisted diagnosis and treatment system for the nuclear medicine ward and the application method, a semi-autonomous and remote interaction mode is used for replacing medical staff to execute face-to-face diagnosis and treatment behaviors with patients, and non-contact diagnosis and treatment are achieved through human-machine-patient high cooperation in the whole diagnosis and treatment process.

The invention relates to a nano preparation for delivering antibiotics based on plant extracts and application of the nano preparation, and belongs to the technical field of nano preparations. In order to solve the problems of low bioavailability and low action efficiency of oral administration or intravenous injection of antibiotics in the lung disease treatment process, the invention provides a nano preparation for delivering antibiotics based on plant extracts. The mass volume ratio of the antibiotics to the plant extract in the nano preparation is (1-10) mg: (20-100) mu L. The nano preparation disclosed by the invention can obviously inhibit the migration of fibroblasts, has an obvious bacteriostatic effect and can reduce the density of microorganisms in lungs; positive charges carried by the material are combined with negative charges on the surface of a bacterial cell membrane, transmembrane substance transfer on the bacterial cell membrane is affected, bacterial metabolism and reproduction are affected, adjustment of pulmonary symbiotic bacteria is better achieved, and the pulmonary fibrosis progress can be relieved. The nano preparation has the advantages of small toxic and side effects, good patient compliance, high encapsulation efficiency and the like.

A system and method for tracking and administering liquid intravenous medications in a hospital, clinic, or patient residence, including recording information onto a short range communication device affixed to a liquid container in a hospital pharmaceutical filling or compounding center, the information including drug information, patient information, and IV administration information, transferring the liquid container to a patient's bedside, programming an infusion course into a bedside IV infusion pump by enabling the pump to read the encoded information on the communication device, and disposing of the liquid container and any residual drug in a smart disposal bin that reads the communication device and weighs the container. The disposal bin may confirm the chemical contents of the container.

The invention discloses a method for promoting diabetic fracture healing by using bone marrow mesenchymal stem cell exosomes, which comprises the following steps: separating MSCs (mesenchymal stem cells) from the bone marrow of a diabetic patient, culturing and extracting the exosomes; the method comprises the following steps: extracting an exosome from a bone fracture part, performing quantitative analysis on the extracted exosome, injecting the exosome into the bone fracture part in a manner of intravenous injection, local injection or minimally invasive injection, continuously treating, promoting proliferation and differentiation of osteoblasts by miRNA or mRNA in the exosome through targeting cells, enhancing angiogenesis, and further accelerating fracture healing. According to the exosome, proliferation and differentiation of osteoblasts are promoted through miRNA or mRNA in the exosome, the synthesis capacity of bone matrixes of the osteoblasts is enhanced, so that fracture healing is accelerated, meanwhile, the exosome provides necessary blood supply for fracture healing by adjusting vascular endothelial cells and promoting angiogenesis, and the repair capacity of fracture parts is effectively improved.

A drug delivery system includes a packaging housing a first component including at least one of a drug product, a diluent, a saline solution, or an IV stabilizing solution (“IVSS”) and a second component comprising at least one of the drug product, the diluent, the saline solution, and the IVSS, the first component being different than the second component. The first component is disposed in a first container in a storage state and the first container is positioned in a first compartment of the packaging housing. The second component is disposed in a second container in a storage state and the second container is positioned in a second compartment of the packaging housing. At least one of the first compartment and the second compartment may include an individual seal and wherein each of the individual seals and the first and second compartments are sterilized.

A liquid transfer device is provided having a trifurcated body that includes a vial adapter at a first end configured to telescopically mount on the crown of an IV bottle to puncture a stopper in the crown with a cannula, an IV port extending from an opposing second end of the trifurcated body, and a needleless self-sealing port extending from a third end of the trifurcated body and configured to couple with the male connector of an additive transfer device. Methods of using the liquid transfer device with an IV bottle, additive transfer device, and an infusion set to prepare an infusion liquid for administration to a patient are also provided.

The invention belongs to the technical field of drug delivery, and particularly relates to an M-coated PLGA-10BX compound as well as a preparation method and application thereof. The preparation method comprises the following steps: preparing 10B-enriched boron nitride (h-10BN); extracting a cell membrane of the macrophage RAW264.7; polylactic acid-glycolic acid copolymer (PLGA) nano particles loaded with h-10BN are prepared; and finally, the bionic nano platform M (at) PLGA-10BN based on the macrophage membrane is prepared. The bionic nano-platform prepared by the invention is uniform in particle size and morphology, has relatively high biological safety, and has no obvious damage to various tissues and visceral organs. The compound can be used as a general platform for boron compound delivery, can also be used as an immune activator, is suitable for intravenous injection administration, and expands the application of boron neutron capture therapy (BNCT) in treatment of glioblastoma (GBM).

The invention relates to a noninvasive solid tumor internal hypoxia condition detection method, which comprises: chemically modifying a near-infrared two-region fluorophore, an oxygen sensitive group and a tumor targeting group to construct a composite probe, collecting fluorescence and photoacoustic signals of a tumor region after intravenous injection, carrying out de-noising analysis, and combining with multiple parameters to solve hypoxia concentration change, a four-dimensional space-time distribution map is constructed by fusing vascular topological data, and individualized calibration is realized through microfluidic simulation and Bayesian optimization. Compared with a traditional invasive detection and single-mode imaging technology, the advantages of bimodal signals are integrated in a breakthrough mode, non-invasive, real-time and high-resolution dynamic hypoxia monitoring is achieved, acute and chronic hypoxia areas are accurately distinguished, tumor blood vessel heterogeneity interference is reduced through personalized parameter calibration, and the accuracy of hypoxia monitoring is improved. High-precision spatio-temporal data support based on hypoxia microenvironment monitoring is provided for solid tumor radiotherapy target planning, chemotherapy drug delivery optimization, chemotherapy drug resistance and curative effect prediction and evaluation and tumor metastasis progress risk analysis.

The invention provides a method for determining < 99m > Tc-DOTA-FAPI-46 and metabolites of < 99m > Tc-DOTA-FAPI-46 in a biological sample. The determination method comprises the following steps: after performing intravenous injection on < 99m > Tc-DOTA-FAPI-46, collecting the sample; adding an organic solvent into the collected sample, uniformly mixing, centrifuging, taking supernate, blow-drying the supernate, dissolving the supernate in normal saline, and concentrating by 1-10 times to obtain a sample injection solution, and the volume ratio of the collected sample to the added organic solvent is 1: (1-3); the sample injection solution is taken and put into high performance liquid chromatography for determination, a detector is a radioactive detector, a chromatographic column is a reversed-phase chromatographic column, and the elution mode is gradient elution; and calculating the proportion of the peak areas of < 99m > Tc-DOTA-FAPI-46, radioactive metabolites and radioactive impurities in the sample in the total radioactive components according to the determined peak area containing the radioactive components. By setting proper pretreatment conditions and liquid chromatogram detection conditions, radioactive metabolites can be detected in a biological sample, the detection sensitivity and accuracy are improved, and the in-vivo stability of drugs can be accurately and efficiently evaluated.

The invention relates to the technical field of biomedicine, in particular to a mouse intrahepatic bile duct cancer cell strain and a construction method and application thereof, the cell strain is named as mouse intrahepatic bile duct cancer cell strain KP-ICC and preserved in China Center for Type Culture Collection (CCTCC), and the preservation number is CCTCC NO: C202574; the cell strain is derived from a KrasG12D / Tp53flox / flox C57BL / 6J mouse, a spontaneous tumor model is constructed through high-pressure hydrodynamic tail vein injection of pT3-Cre and a sleep beauty transposase plasmid, and the spontaneous tumor model is obtained through in-vitro culture, passage, monoclonal screening and tumorigenicity verification. The KP-ICC cell strain naturally has chemotherapy-immune combined treatment drug resistance and ferroptosis resistance characteristics, and can be widely applied to the fields of intrahepatic cholangiocarcinoma drug resistance mechanism research, drug resistance reversing, combined treatment drug development, drug resistance animal model establishment and the like.

The invention discloses a method for constructing an atrial fibrillation small animal model through succinic acid induction and application, and the method comprises the following steps: in an animal model construction period, enabling a small animal to ingest an aqueous solution containing succinic acid or all pharmaceutically acceptable salts of succinic acid every day, and finishing the modeling period to obtain the animal model. Compared with a traditional angiotensin AngII administration method, the atrial fibrillation small animal model has the advantages that the cost of a medicine for constructing the animal model is lower, the economic benefit is higher, and the atrial fibrillation induction effect is better; the model represents the most common atrial fibrillation type in clinic, and compared with an acute transient atrial fibrillation model, the research and application range is wider; compared with tail vein injection, intraperitoneal injection, subcutaneous pump burying and other modes, the non-creative model has the advantages that damage to small animals is smaller, and the requirement for the operation technology is low.

The present invention relates to a novel long-acting injectable composition comprising finasteride for the prevention or treatment of androgenetic alopecia. The composition inhibits type II 5α-reductase with a single injection lasting over one month, thereby suppressing the conversion of testosterone to DHT and reducing androgen-mediated follicular miniaturization. In addition, after injection into the body, the average elimination half-life (T1 / 2el) of finasteride can be increased to enhance stability and provide more predictable and uniform therapeutic effects compared to oral formulations.

The invention relates to the technical field of medicines, and discloses a drug delivery bionic carrier as well as a preparation method and application thereof. Most of anti-tumor drugs are low in delivery efficiency through intravenous injection, the anti-tumor drugs are'inactivated 'by lysosomes after entering cells and fail, and the drug failure approach is a main reason for reduction of the effectiveness of most of the anti-tumor drugs delivered through intravenous injection. In order to improve the efficiency of targeted delivery of anti-tumor drugs through intravenous injection, a bionic carrier formed by wrapping chalk with a cell membrane is provided to load the anti-tumor drugs, and specifically, chalk releases carbon dioxide in lysosome to break through the lysosome and promote the drugs to escape from the lysosome, so that targeted delivery and intracellular positioning release of the drugs are realized; the anti-tumor effect of the medicine is remarkably improved while the biocompatibility of the carrier is not influenced, and a scientific basis is provided for targeted delivery of the medicine and tumor treatment.

The invention provides a device for injecting caudal veins of mice, which relates to the field of biomedical engineering, and comprises a fixed table body, a mouse body fixing cylinder, a placing groove, a mouse tail fixing table, an overturning support frame, an overturning driving motor, a clamping chuck, a fixed adjusting mechanism and a tail overturning driving mechanism, the mouse body fixing cylinder is fixedly connected to the upper portion of the fixing table body. The placing groove is formed in the upper part of the mouse body fixing cylinder; the rat tail fixing table is fixedly connected to the rear side of the upper portion of the fixing table body. The overturning driving motor is fixedly connected to the upper end of the rear portion of the overturning supporting frame. The clamping chuck is rotationally connected to the front portion of the overturning supporting frame. The fixed adjusting mechanism is arranged on the upper portion of the interior of the fixed table body. The tail turning driving mechanism is arranged behind the mouse tail fixing table, intravenous injection operation of experimenters is facilitated, the mouse tail intravenous injection operation efficiency is improved, and the problems that the experimenters need to twist the mouse tail with one hand and operate an injector with the other hand during injection, and operation is inconvenient are solved.

The invention belongs to the technical field of biological medicines, and particularly relates to a microneedle of a drug with a short half-life period as well as a preparation method and application of the microneedle. The bipolar controllable release microneedle is provided for drugs with short half-life periods, long-acting percutaneous minimally invasive drug delivery is achieved, the convenience and comfort of a patient in drug use are greatly improved, controllable plasma concentration maintaining time can be achieved by adjusting the proportion of the first-stage release phase and the second-stage release phase, and the personalized analgesic drug delivery requirement is met. Besides, by taking an opioid analgesic administration strategy as an entry point, the precise controllable two-stage release microneedle of the biphasic matrix carried medicine is innovatively provided, a new dosage form is developed for the opioid analgesic medicine, and compared with an existing intravenous injection administration mode, the analgesic time can be prolonged by 24 times, and the analgesic effect of the medicine is greatly improved.

The invention belongs to the technical field of drug co-delivery, and particularly relates to a nano-platform based on attenuated bacterial outer membrane vesicles and capable of achieving co-delivery of siRNA and adriamycin and a preparation method of the nano-platform. The preparation method comprises the following steps: synthesizing an ROS response type cationic polymer PTP; the preparation method comprises the following steps: preparing aptamer-DOX; preparing an ROS (reactive oxygen species) response type positive electric nano core PTP / 47aD; extracting and purifying the [delta] msbB OMVs; synthesizing a target functional unit DSPE-PEG2k-Angiopep-2 (Distearoyl Phosphate Polyethylene Glycol 2k-Angiopep-2); finally, the ROS response type co-delivery nano platform AO (at) PTP / 47aD is prepared and obtained. The co-delivery nano-platform prepared by the invention is relatively small in particle size, uniform in morphology and relatively high in biological safety, and has no obvious damage to various tissues and visceral organs. The glioblastoma immunopotentiator can be used as a general platform for gene delivery, can also be used as an immune activator, is suitable for intravenous injection administration, and can comprehensively overcome immune resistance of glioblastoma.